Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations

Abstract excerpt

Multiple myeloma (MM) is a clinically and genetically heterogenous cancer where tumour cells have dysregulated expression of a D-type cyclin, often in association with a recurrent IgH translocation. Patients whose tumour cells express cyclin D2, with the translocation t(4;14) or t(14;16), generally have more proliferative disease and inferior outcomes. The phosphatidylinositol-3-kinase (PI3K) pathway is a major...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Multiple Myeloma Research and Treatments
• Share to PI3K/AKT/mTOR signaling in cancer